Hao Yuxuan, Zhang Xiaoye, Yu Li
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Front Oncol. 2022 Aug 16;12:911906. doi: 10.3389/fonc.2022.911906. eCollection 2022.
Immune checkpoint inhibitors (ICIs) have shown definite therapeutic effects in various types of cancers, especially non-small cell lung cancer (NSCLC). However, ICIs have unique side effects, called immune-related adverse events (irAEs), which can occur in various systems throughout the body. Among such irAEs, immune checkpoint inhibitor-related pneumonitis (ICI-P) is a fatal adverse reaction. In this review, we discussed the risk factors, pathogenesis, clinical characteristics, radiological manifestations, pathological features, diagnosis, grading, and management of ICI-P in NSCLC and the relationship between ICI-P and the efficacy of ICI therapy. In addition, we discussed the predictive factors for ICI-P. This review will play a crucial role in the prediction, evaluation, and management of ICI-P for widespread application of immunotherapy.
免疫检查点抑制剂（ICIs）已在多种类型的癌症中显示出确切的治疗效果，尤其是非小细胞肺癌（NSCLC）。然而，ICIs具有独特的副作用，称为免疫相关不良事件（irAEs），可发生于全身各个系统。在这些irAEs中，免疫检查点抑制剂相关肺炎（ICI-P）是一种致命的不良反应。在本综述中，我们讨论了NSCLC中ICI-P的危险因素、发病机制、临床特征、影像学表现、病理特征、诊断、分级和管理，以及ICI-P与ICI治疗疗效之间的关系。此外，我们还讨论了ICI-P的预测因素。本综述将在ICI-P的预测、评估和管理中发挥关键作用，以促进免疫疗法的广泛应用。
